Cargando…

B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection

Solid organs have been transplanted for decades. Since the improvement in graft selection and in medical and surgical procedures, the likelihood of graft function after 1 year is now close to 90%. Nonetheless even well-matched recipients continue to need medications for the rest of their lives hence...

Descripción completa

Detalles Bibliográficos
Autor principal: Dalloul, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865384/
https://www.ncbi.nlm.nih.gov/pubmed/24381571
http://dx.doi.org/10.3389/fimmu.2013.00444
_version_ 1782296032534593536
author Dalloul, Ali
author_facet Dalloul, Ali
author_sort Dalloul, Ali
collection PubMed
description Solid organs have been transplanted for decades. Since the improvement in graft selection and in medical and surgical procedures, the likelihood of graft function after 1 year is now close to 90%. Nonetheless even well-matched recipients continue to need medications for the rest of their lives hence adverse side effects and enhanced morbidity. Understanding Immune rejection mechanisms, is of increasing importance since the greater use of living-unrelated donors and genetically unmatched individuals. Chronic rejection is devoted to T-cells, however the role of B-cells in rejection has been appreciated recently by the observation that B-cell depletion improve graft survival. By contrast however, B-cells can be beneficial to the grafted tissue. This protective effect is secondary to either the secretion of protective antibodies or the induction of B-cells that restrain excessive inflammatory responses, chiefly by local provision of IL-10, or inhibit effector T-cells by direct cellular interactions. As a proof of concept B-cell-mediated infectious transplantation tolerance could be achieved in animal models, and evidence emerged that the presence of such B-cells in transplanted patients correlate with a favorable outcome. Among these populations, regulatory B-cells constitute a recently described population. These cells may develop as a feedback mechanism to prevent uncontrolled reactivity to antigens and inflammatory stimuli. The difficult task for the clinician, is to quantify the respective ratios and functions of “tolerant” vs. effector B-cells within a transplanted organ, at a given time point in order to modulate B-cell-directed therapy. Several receptors at the B-cell membrane as well as signaling molecules, can now be targeted for this purpose. Understanding the temporal expansion of regulatory B-cells in grafted patients and the stimuli that activate them will help in the future to implement specific strategies aimed at fighting chronic allograft rejection.
format Online
Article
Text
id pubmed-3865384
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38653842013-12-31 B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection Dalloul, Ali Front Immunol Immunology Solid organs have been transplanted for decades. Since the improvement in graft selection and in medical and surgical procedures, the likelihood of graft function after 1 year is now close to 90%. Nonetheless even well-matched recipients continue to need medications for the rest of their lives hence adverse side effects and enhanced morbidity. Understanding Immune rejection mechanisms, is of increasing importance since the greater use of living-unrelated donors and genetically unmatched individuals. Chronic rejection is devoted to T-cells, however the role of B-cells in rejection has been appreciated recently by the observation that B-cell depletion improve graft survival. By contrast however, B-cells can be beneficial to the grafted tissue. This protective effect is secondary to either the secretion of protective antibodies or the induction of B-cells that restrain excessive inflammatory responses, chiefly by local provision of IL-10, or inhibit effector T-cells by direct cellular interactions. As a proof of concept B-cell-mediated infectious transplantation tolerance could be achieved in animal models, and evidence emerged that the presence of such B-cells in transplanted patients correlate with a favorable outcome. Among these populations, regulatory B-cells constitute a recently described population. These cells may develop as a feedback mechanism to prevent uncontrolled reactivity to antigens and inflammatory stimuli. The difficult task for the clinician, is to quantify the respective ratios and functions of “tolerant” vs. effector B-cells within a transplanted organ, at a given time point in order to modulate B-cell-directed therapy. Several receptors at the B-cell membrane as well as signaling molecules, can now be targeted for this purpose. Understanding the temporal expansion of regulatory B-cells in grafted patients and the stimuli that activate them will help in the future to implement specific strategies aimed at fighting chronic allograft rejection. Frontiers Media S.A. 2013-12-17 /pmc/articles/PMC3865384/ /pubmed/24381571 http://dx.doi.org/10.3389/fimmu.2013.00444 Text en Copyright © 2013 Dalloul. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Dalloul, Ali
B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection
title B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection
title_full B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection
title_fullStr B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection
title_full_unstemmed B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection
title_short B-Cell-Mediated Strategies to Fight Chronic Allograft Rejection
title_sort b-cell-mediated strategies to fight chronic allograft rejection
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865384/
https://www.ncbi.nlm.nih.gov/pubmed/24381571
http://dx.doi.org/10.3389/fimmu.2013.00444
work_keys_str_mv AT dalloulali bcellmediatedstrategiestofightchronicallograftrejection